MarketPulse

immunological diseases

2 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Vera Therapeutics as Kidney Drug Nears FDA Decision

Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.
VERAFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vera Therapeutics Bolsters Board with Royalty Pharma Executive Ahead of Key Drug Launch

Vera Therapeutics appoints Christopher Hite, Royalty Pharma EVP, to board as the biotech prepares for atacicept launch in IgA nephropathy treatment.
RPRXVERAbiopharmaceuticalIgA nephropathy